This content is from:xinyabo体育app
Health Care – Pharmaceuticals/Major: 2012 Third
Mark Schoenebaum — No. 1 in Biotechnology since 2005 — broadened his coverage area last year to include large-cap pharmaceuticals and scores a third-place debut in this sector.
|
Mark Schoenebaum — No. 1 in Biotechnology since 2005 — broadened his coverage area last year to include large-cap pharmaceuticals and scores a third-place debut in this sector. The ISI Group analyst began tracking Merck & Co. in late January and urged clients to buy the stock, at $37.93, on the successful clinical trials of its osteoporosis drug odanacatib. “We think the probability of success is high and that the Street has dramatically underestimated how big this drug can be,” Schoenebaum says. The Whitehouse Station, New Jersey–based company’s shares had advanced 13.5 percent, to $43.05, by the end of August. Schoenebaum remains bullish on this and other stocks in the group, which are trading below market value and offering generous dividend yields: “I see that as continuing and am optimistic that companies will do more cost cutting and restructuring,” he says. One portfolio manager praises the analyst’s ability to “drill down the key points and explain through videoconference calls the events that are impacting stocks.” RUNNER(S)-UP Jamilu Rubin Goldman, Sachs & Co. Christopher Schott J.P. Morgan |